Doris Quon, MD
Hematology · Los Angeles, CANPI 1578589271
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $910,181 of the $1,461,647 with a category attached, or 62.3%. It is spread thinly across 60 manufacturers, the largest accounting for just 22.0%. Among hematology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,467 payments — averaging $996.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$321K
- Novo Nordisk$302K
- CSL Behring$205K
- HEMA Biologics, LLC$184K
- Biomarin Pharmaceutical Inc.$115K
- Genentech USA, Inc.$95K
- plus $240K from 54 others
Across 165 payments — averaging $3572.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$282K
- Genentech, Inc.$81K
- Bayer$52K
- Sanofi US Services Inc.$38K
- HEMA Biologics, LLC$31K
- Bioverativ Therapeutics Inc.$27K
- plus $78K from 6 others
What the payments were for
- Consulting fees$354,66924%
- Speaking & faculty fees$910,18162%
- Travel & lodging$168,00411%
- Food & beverage$28,6752%
- Education$1060%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,461,647 in reported general payments places this provider in the 95th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Los Angeles
- Ilene WeitzLos Angeles$631K
- Caroline PiatekLos Angeles$391K
- Anil TulpuleLos Angeles$79K
- Imran SiddiqiLos Angeles$59K
- Carol KasperLos Angeles$58K
- Everett MeyerStanford$2.1M
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Hope RugoSan Francisco$537K
- Alexey DanilovDuarte$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.